Application Sponsors
ANDA 204591 | TEVA PHARMS USA INC | |
Marketing Status
None (Tentative Approval) | 001 |
None (Tentative Approval) | 002 |
None (Tentative Approval) | 003 |
Application Products
001 | TABLET, EXTENDED RELEASE;ORAL | 50MG;500MG | 0 | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE |
002 | TABLET, EXTENDED RELEASE;ORAL | 50MG;1000MG | 0 | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE |
003 | TABLET, EXTENDED RELEASE;ORAL | 100MG;1000MG | 0 | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE |
FDA Submissions
UNKNOWN; | ORIG | 1 | TA | 2015-09-29 | STANDARD |
Submissions Property Types
CDER Filings
TEVA PHARMS USA INC
cder:Array
(
[0] => Array
(
[ApplNo] => 204591
[companyName] => TEVA PHARMS USA INC
[docInserts] => ["",""]
[products] => [{"drugName":"SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE","activeIngredients":"SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE","strength":"50MG;500MG","dosageForm":"TABLET, EXTENDED RELEASE;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE","activeIngredients":"SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE","strength":"50MG;1000MG","dosageForm":"TABLET, EXTENDED RELEASE;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE","activeIngredients":"SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE","strength":"100MG;1000MG","dosageForm":"TABLET, EXTENDED RELEASE;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"09\/29\/2015","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2015-09-29
)
)